Sanofi's Aubagio for MS accepted for US review alongside new data boost
This article was originally published in Scrip
In reporting new data from a pivotal trial of its oral multiple sclerosis therapy, teriflunomide (Aubagio), Sanofi also said that the US FDA has accepted for review the new drug application (NDA) for the product as a potential treatment for relapsing forms of multiple sclerosis (MS). The company added that it is still aiming for a European submission in the first quarter of next year.
You may also be interested in...
Danish firm Topotarget said it was 'very confident' that it will be able to raise its first milestone from partner, Spectrum Pharmaceuticals, by the third quarter as it reported that final top-line data confirm that the primary endpoint was met in the Phase II BELIEF trial investigating an intravenous formulation of the histone deacetylase (HDAC) inhibitor, belinostat, for peripheral T-cell lymphoma (PTCL).
AstraZeneca's Caprelsa (vandetanib) has become the first treatment to be approved for advanced medullary thyroid cancer (MTC) in Europe after being granted marketing authorisation by the European Commission.
Despite reporting positive weight loss data from the third of four Phase IIIa trials from the SCALE program investigating liraglutide (Victoza) for obesity Novo Nordisk has failed to dazzle analysts who have questioned the commercial potential of the drug in this arena.